SCHEMBL2117925

SCHEMBL2117925

Cc1ccc(-n2c(-c3ccccc3C)nc3c(cnn3-c3ccccc3)c2=O)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.71
TP53 P04637 4/20 0.71
SMN1; SMN2 Q16637 5/20 0.62
NPSR1 Q6W5P4 3/20 0.62
GRM1 Q13255 3/20 0.61
GRM5 P41594 1/20 0.60
TSHR P16473 4/20 0.58
HTT P42858 3/20 0.58
LMNA P02545 2/20 0.58
DPP4 P27487 1/20 0.58
ALDH1A1 P00352 1/20 0.58
HPGD P15428 1/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58
POLB P06746 1/20 0.57
KDR P35968 1/20 0.57
THRB P10828 1/20 0.56
KDM4E B2RXH2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117655 0.91 SMN1; SMN2 (0.61) MAPTTP53SMN1; SMN2GRM1GRM5
SCHEMBL1753558 0.91 GRM1 (0.73) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL1753296 0.89 TP53 (0.78) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL2117294 0.87 DPP4 (0.57) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL2115952 0.87 MAPT (0.87) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL2116994 0.87 MAPT (0.89) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL2117605 0.85 MAPT (0.87) MAPTTP53SMN1; SMN2NPSR1GRM1
SCHEMBL2115828 0.85 TP53 (0.74) MAPTTP53SMN1; SMN2GRM1GRM5
SCHEMBL1689284 0.83 MAPT (0.71) MAPTTP53SMN1; SMN2GRM1GRM5
SCHEMBL2116120 0.83 TP53 (1.00) MAPTTP53SMN1; SMN2NPSR1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US claimed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
US-20070299047-A1 Combination of Organic Compounds MAHER WILLIAM 2007-12-27 US disclosed
EP-1791600-A1 COMBINATION OF ORGANIC COMPOUNDS Novartis AG (CH) 2007-06-06 EP disclosed
WO-2006029349-A1 COMBINATION OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299047-A1 Combination of Organic Compounds GLP1R, PPARG, GCGR MAPT 4328/4885TP53 4351/4885SMN1; SMN2 4363/4885
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH MAPT 1780/4885TP53 4640/4885SMN1; SMN2 3746/4885
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH MAPT 1780/4885TP53 4640/4885SMN1; SMN2 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.